Camlin Fine Sciences Limited · NSE:CAMLINFINE
Camlin Fine Sciences — H1 FY2022 Earnings Presentation
21 slides from Camlin Fine Sciences's earnings presentation, November 2021
Slide 1: Earnings Presentation H1 / Q2-FY22
EARNINGS PRESENTATION H1 / Q2-FY22
Slide 2: Snapshot
Snapshot One of the few end-to-end Strong management team with Global experience with local 5 Manufacturing Facilities integrated specialty chemicals experienced industry professionals presence 2 R&D Centres company 5 Application Labs Diversified product basket of over Established customer base of o
Slide 3: About the Company
About the Company • Camlin Fine Sciences Limited (CFS) was formed in 2006 after de-merging the fine Total Operational Revenue (INR Mn) chemical business from Camlin Ltd and got listed on the BSE and NSE in 2007 and 2011, respectively. 11,871 10,491 • It is a vertically integrated company, engaged in
Slide 4: H1 / Q2-FY22 Financial Overview
H1 / Q2-FY22 FINANCIAL OVERVIEW
Slide 5: H1 / Q2-FY22 Financial Highlights
H1 / Q2-FY22 Financial Highlights Q2-FY22 Financial Highlights (Consolidated): Q2-FY22 Financial Highlights (Standalone): INR 3,112 Mn INR 227 Mn INR 277 Mn INR (39) Mn INR 1,382 Mn INR 29 Mn INR 39 Mn INR (70) Mn Total Revenue EBITDA Adjusted EBITDA PAT Total Revenue EBITDA Adjusted EBITDA PAT 7.30
Slide 6: H1 / Q2-FY22 Operational Highlights (Consolidated)
H1 / Q2-FY22 Operational Highlights (Consolidated) • Demand remained strong however reduction in turnover can be primarily attributed to tepid performance of CFS India One time impacts • Loss of production compared to Q1-FY22 • Due to disruptions in logistics & supply chain • Technical issues in sca
Slide 7: Q2-FY22 Standalone Income Statement (Ind-AS)
Q2-FY22 Standalone Income Statement (Ind-AS) Income Statement (Mn) Q2-FY22 Q1-FY22 Q-o-Q Q2-FY21 Y-o-Y Operational Revenue 1,382 1,457 (5.2)% 1,468 (5.9)% Total Expenses 1,352 1,265 6.9% 1,397 (3.2)% Operational EBITDA 29 192 (84.9)% 71 (59.2)% Operational EBITDA Margins (%) 2.13% 13.18% NA 4.84% (2
Slide 8: H1-FY22 Standalone Income Statement (Ind-AS)
H1-FY22 Standalone Income Statement (Ind-AS) Income Statement (Mn) H1-FY22 H1-FY21 Y-o-Y Operational Revenue 2,839 2,679 6.0% Total Expenses 2,608 2,446 6.6% Operational EBITDA 231 233 (0.9)% Operational EBITDA Margins (%) 8.13% 8.70% (57) Bps Adjusted EBITDA* 231 302 (23.6)% Adjusted EBITDA Margins
Slide 9: Q2-FY22 Consolidated Income Statement (Ind-AS)
Q2-FY22 Consolidated Income Statement (Ind-AS) Income Statement (INR Mn) Q2-FY22 Q1-FY22 Q-o-Q Q2-FY21 Y-o-Y Operational Revenue 3,112 3,308 (5.9)% 2,568 21.2% Total Expenses 2,885 2,852 1.2% 2,232 29.3% Operational EBITDA 227 456 (50.2)% 336 (32.4)% Operational EBITDA Margins (%) 7.30% 13.78% (648)
Slide 10: H1-FY22 Consolidated Income Statement (Ind-AS)
H1-FY22 Consolidated Income Statement (Ind-AS) Income Statement (INR Mn) H1-FY22 H1-FY21 Y-o-Y Operational Revenue 6,420 5,626 13.6% Total Expenses 5,687 4,778 19.0% Operational EBITDA 733 848 (13.5)% Operational EBITDA Margins (%) 11.42% 15.07% (365) Bps Adjusted EBITDA* 733 968 (24.3)% Adjusted EB
Slide 11: Country Overview
COUNTRY OVERVIEW
Slide 12: Country Wise Quarterly Performance
Country Wise Quarterly Performance CFS India CFS Mexico CFS Europe Quarterly Operational 1,468 1,457 1,117 1,382 Revenue (INR Mn) 1,060 751 762 951 607 Q2-FY21 Q1-FY22 Q2-FY22 Q2-FY21 Q1-FY22 Q2-FY22 Q2-FY21 Q1-FY22 Q2-FY22 CFS Brazil CFS Wanglong CFS North America Quarterly Operational 167 Revenue
Slide 13: Country Wise Yearly Performance
Country Wise Yearly Performance CFS India CFS Mexico CFS Europe Operational Revenue 2,735 3,762 5,798 6,000 2,571 3,296 5,481 3,091 2,172 (INR Mn) 2,771 4,050 1,642 2,177 1,513 2,839 FY18 FY19 FY20 FY21 H1-FY22 FY18 FY19 FY20 FY21 H1-FY22 FY18 FY19 FY20 FY21 H1-FY22 CFS Brazil CFS Wanglong CFS North
Slide 14: Historical Financial Overview
HISTORICAL FINANCIAL OVERVIEW
Slide 15: Historical Standalone Income Statement
Historical Standalone Income Statement Particulars (INR Mn) FY19 FY20 FY21 H1-FY22 Operational Income 5,481 5,798 6,000 2,839 Total Expenses 5,182 5,201 5,382 2,608 EBITDA 299 597 618 231 EBITDA Margin 5.46% 10.30% 10.30% 8.13% Depreciation 91 113 193 131 Finance Cost 203 281 325 171 Other Income 13
Slide 16: Standalone Balance Sheet
Standalone Balance Sheet H1- H1- Particulars (INR Mn) FY20 FY21 Particulars (INR Mn) FY20 FY21 FY22 FY22 EQUITY 3,768 4,646 5,064 Non-Current Assets 3,802 4,087 4,826 a) Equity Share Capital 121 127 128 a) Property, Plant and Equipment 686 2,457 2,428 b) Other Equity 3,647 4,519 4,936 b) Capital Wor
Slide 17: Historical Consolidated Income Statement
Historical Consolidated Income Statement PARTICULARS (INR Mn) FY19 FY20 FY21 H1-FY22 Operational Income 8,922 10,491 11,871 6,420 Total Expenses 8,235 9,184 10,052 5,687 EBITDA 687 1,307 1,819 733 EBITDA Margin 7.70% 12.46% 15.32% 11.42% Depreciation 290 328 443 268 Finance Cost 367 431 375 192 Othe
Slide 18: Consolidated Balance Sheet
Consolidated Balance Sheet PARTICULARS (INR Mn) FY20 FY21 H1-FY22 PARTICULARS (INR Mn) FY20 FY21 H1-FY22 EQUITY 4,601 7,131 7,737 Non-Current Assets 5,591 6,869 7,744 a) Equity Share Capital 121 127 128 a) Property, Plant and Equipment 2,034 4,818 4,753 b) Capital Work In Progress 1,761 237 843 b) O
Slide 19: Consolidated Financial Highlights
Consolidated Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margin (%) Debt to EBITDA 28.44 4,000 11,871 2,100 15.32% 18.00% 2,000 10,491 1,800 16.00% 12.46% 1,819 11.42% 14.00% 0,000 8,922 1,500 7,228 12.00% 8,000 6,420 1,200 7.70% 10.00% 6,000 900 8.00% 1,307 6.00% 6.99
Slide 20: Capital Markets
Capital Markets 110.00% 90.00% 70.00% 50.00% 30.00% 10.00% -10.00%Oct-20 Nov-20 Dec-20 Jan-21 Feb-21 Mar-21 Apr-21 May-21 Jun-21 Jul-21 Aug-21 Sep-21 -30.00% Sensex Camlin Price Data (30th September, 2021) INR Shareholding Pattern as on 30th September, 2021 Face Value 1.0 Promoters 21.61% Market Pri
Slide 21: Disclaimer
Disclaimer Camlin Fine Sciences Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all e
Camlin Fine Sciences — H1 FY2022 Earnings Presentation on 6ix